Genomic tests for selecting therapy in adjuvant treatment of ER+ breast cancer (BC)

Genomic tests for selecting therapy in adjuvant treatment of ER+ breast cancer (BC)

Bibliographic Details
Main Author:	M. Piccart
Format:	Article
Language:	English
Published:	Elsevier 2021-04-01
Series:	Breast
Online Access:	http://www.sciencedirect.com/science/article/pii/S0960977621000606

Similar Items

ADJUVANT HORMONE THERAPY ELIGIBILITY OF PREMENOPAUSAL WOMEN WITH ER+ BREAST CANCER
by: V. F. SEMIGLAZOV, et al.
Published: (2017-06-01)

Extended Adjuvant Endocrine Treatment in Luminal Breast Cancers in the Era of Genomic Tests
by: Mariarosaria Saponaro, et al.
Published: (2022-11-01)

ADVANCES IN TARGETED THERAPY FOR BREAST CANCER (BC)
by: Gabriel N. Hortobagyi
Published: (2005-01-01)

Late effects of adjuvant chemotherapy adumbrate dormancy complexity in breast cancer
by: Romano Demicheli, et al.
Published: (2020-08-01)

Efficacy of Metformin as Adjuvant Therapy in Metastatic Breast Cancer Treatment
by: Nourhan M. Essa, et al.
Published: (2022-09-01)

Omission of adjuvant therapy in stage I clear cell ovarian cancer: Review of the BC Cancer experience
by: Shiru L. Liu, et al.
Published: (2020-02-01)

Adjuvant treatment for breast cancer
by: Flatley, M, et al.
Published: (2019)

Adjuvant therapy for early breast cancer
by: I. V. Vysotskaya
Published: (2014-07-01)

Network Modeling of Complex Time-Dependent Changes in Patient Adherence to Adjuvant Endocrine Treatment in ER+ Breast Cancer
by: Eileen H. Shinn, et al.
Published: (2022-07-01)

SA 8.3 Emerging new treatments in HER2 positive breast cancer
by: M. Piccart
Published: (2023-03-01)

THE EBCTCG OVERVIEW OF ADJUVANT THERAPY OF BREAST-CANCER
by: Gray, R, et al.
Published: (1994)

Taxane therapy in the adjuvant treatment of breast cancer in Italy: economic evaluation
by: Simona Ravera, et al.
Published: (2006-03-01)

The Value of Serum Biomarkers (Bc1, Bc2, Bc3) in the Diagnosis of Early Breast Cancer
by: Kemal Atahan, Hakan Küpeli, Serhat Gür, Türkan Yiğitbaşı, Yasemin Baskın, Seyran Yiğit, Mehmet Deniz, Atilla Çökmez, Ercüment Tarcan
Published: (2011-01-01)

Metformin as an adjuvant in breast cancer treatment
by: Mohsin HK Roshan, et al.
Published: (2019-07-01)

Taxanes in adjuvant and neoadjuvant therapy for breast cancer
by: S. V. Limareva
Published: (2014-08-01)

Association of oestrogen receptor beta 2 (ERβ2/ERβcx) with outcome of adjuvant endocrine treatment for primary breast cancer – a retrospective study
by: Holcombe Christopher, et al.
Published: (2007-07-01)

Which adjuvant endocrine therapy for ER-positive non-metastatic breast cancer? EBCTCG-2000 update: Tamoxifen, castration, LHRH-agonists
by: Davies, C, et al.
Published: (2002)

Prospective cohort study of febrile neutropenia in breast cancer patients administered with neoadjuvant and adjuvant chemotherapies: CSPOR-BC FN study
by: Takashi Ishikawa, et al.
Published: (2021-04-01)

Cost-effectiveness of using prognostic information to select women with breast cancer for adjuvant systemic therapy.
by: Williams, C, et al.
Published: (2006)

Cost-effectiveness of using prognostic information to select women with breast cancer for adjuvant systemic therapy
by: C Williams, et al.
Published: (2006-09-01)

Adherence to Adjuvant Endocrine Therapy in Breast Cancer Patients
by: Roberta Rosso, et al.
Published: (2023-01-01)

Adjuvant systemic therapy in older women with breast cancer
by: Leone J, et al.
Published: (2016-07-01)

Is the extension of adjuvant hormone therapy for breast cancer justified?
by: V. F. Semiglazov, et al.
Published: (2020-07-01)

The role of Taxotere in adjuvant therapy for early breast cancer
by: I. V. Kolyadina, et al.
Published: (2014-07-01)

PHARMACOECONOMIC ANALYSIS OF DOCETAXEL IN THE ADJUVANT THERAPY OF BREAST CANCER
by: R. I. Yagudina, et al.
Published: (2015-03-01)

The Role of Adjuvant Radiotherapy in the Treatment of Breast Cancer
by: Iveta Kolářová, et al.
Published: (2024-02-01)

Concurrent chemoradiotherapy in adjuvant treatment of breast cancer
by: Erraki Abdelouahed, et al.
Published: (2009-04-01)

Adjuvant radiotherapy in the conservative treatment of breast cancer
by: Mariela Hernández González, et al.
Published: (2009-09-01)

ESR1 gene amplification and MAP3K mutations are selected during adjuvant endocrine therapies in relapsing Hormone Receptor-positive, HER2-negative breast cancer (HR+ HER2- BC).
by: Lorenzo Ferrando, et al.
Published: (2023-01-01)

Lasofoxifene as a potential treatment for therapy-resistant ER-positive metastatic breast cancer
by: Muriel Lainé, et al.
Published: (2021-05-01)

Potentialities of adjuvant endocrine therapy for breast cancer (Part II)
by: N. Yu. Dobrovolskaya, et al.
Published: (2014-09-01)

The treatment outcomes and the use of adjuvant therapies in breast cancer patients with severe co-morbidities.
by: Jaihong Han, et al.
Published: (2017-01-01)

Gene Expression-Based Predictive Markers for Paclitaxel Treatment in ER+ and ER− Breast Cancer
by: Xiaowen Feng, et al.
Published: (2019-03-01)

LONG-TERM OUTCOMES IN BREAST CANCER PATIENTS AFTER COMPLEX TREATMENT WITH ADJUVANT RADIATION THERAPY
by: K. A. Simonov, et al.
Published: (2016-02-01)

Impact of Oncotype DX testing on ER+ breast cancer treatment and survival in the first decade of use
by: Evelien Schaafsma, et al.
Published: (2021-07-01)

The Prognostic and Predictive Value of Genomic Assays in Guiding Adjuvant Breast Radiation Therapy
by: Sasha J. Beyer, et al.
Published: (2022-12-01)

Interplay of Oncoplastic Reconstruction and Adjuvant Radiation Therapy in Breast Cancer
by: Ryan T. Morse, MD, et al.
Published: (2024-03-01)

Research Status of Systemic Adjuvant Therapy for Early Breast Cancer
by: Wenyu Hu, et al.
Published: (2023-10-01)

Compliance to adjuvant endocrine therapy and survival in breast cancer patients.
by: Chaido Chamalidou, et al.
Published: (2023-01-01)

Understanding adjuvant endocrine therapy persistence in breast Cancer survivors
by: Leah K. Lambert, et al.
Published: (2018-07-01)